Literature DB >> 3087565

Short term high doses of etidronate in Paget's disease of bone.

J A Kanis, R E Gray, S A Murray, N A Hamdy, G H Urwin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3087565      PMCID： PMC1340723          DOI： 10.1136/bmj.292.6536.1667

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  7 in total

1.  Effective short term treatment of Paget's disease with oral etidronate.

Authors:  C J Preston; A J Yates; M N Beneton; R G Russell; R E Gray; R Smith; J A Kanis
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-11

2.  Treatment of osteoporotic fracture.

Authors:  J A Kanis
Journal:  Lancet       Date:  1984-01-07       Impact factor: 79.321

3.  Etidronate and the risk of fractures.

Authors:  C Nagant de Deuxchaisnes; J P Dufour; J P Devogelaer; J P Huaux; W Esselinckx
Journal:  Lancet       Date:  1985-09-14       Impact factor: 79.321

4.  The long-term skeletal effects of EHDP in dogs.

Authors:  L Flora; G S Hassing; G G Cloyd; J A Bevan; A M Parfitt; A R Villanueva
Journal:  Metab Bone Dis Relat Res       Date:  1981

5.  Effects of ethane-1 hydroxy-1, 1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget's disease of bone.

Authors:  C Alexandre; P J Meunier; C Edouard; R A Khairi; C C Johnston
Journal:  Metab Bone Dis Relat Res       Date:  1981

Review 6.  Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP).

Authors:  M Rashid; A Khairi; C Johnston
Journal:  Clin Orthop Relat Res       Date:  1977       Impact factor: 4.176

7.  Review of fracture experience during treatment of Paget's disease of bone with etidronate disodium (EHDP).

Authors:  C C Johnston; R D Altman; R E Canfield; G A Finerman; J D Taulbee; M L Ebert
Journal:  Clin Orthop Relat Res       Date:  1983 Jan-Feb       Impact factor: 4.176
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.